PT - JOURNAL ARTICLE AU - Chen, Shih-Yin AU - Chen, Yu-Chia AU - Liu, Ting-Yuan AU - Chang, Kuan-Cheng AU - Chang, Shih-Sheng AU - Wu, Ning AU - Wu, Donald Lee AU - Dunlap, Rylee Kay AU - Chan, Chia-Jung AU - Tsai, Fuu-Jen TI - Identification of Novel Genes Associated with Atrial Fibrillation and Development of Atrial Fibrillation Predictive Models by Incorporating Polygenic Risk Scores and PheWAS-Derived Risk Factors AID - 10.1101/2023.08.14.23294097 DP - 2023 Jan 01 TA - medRxiv PG - 2023.08.14.23294097 4099 - http://medrxiv.org/content/early/2023/08/16/2023.08.14.23294097.short 4100 - http://medrxiv.org/content/early/2023/08/16/2023.08.14.23294097.full AB - BACKGROUND: Atrial fibrillation (AF) is the most common atrial arrhythmia and is subcategorized into numerous clinical phenotypes. Previous studies demonstrated that early-onset AF was associated with genetic loci among the certain populations.OBJECTIVES: The objective of this study was to develop AF predictive models using AF-associated single-nucleotide polymorphisms (SNPs) selected from the Genome-Wide Association Study (GWAS) of a large cohort of Taiwanese and explore whether the models posed the prediction power for AF.METHODS: 75,121 total subjects including 5,694 AF patients and 69,427 normal controls with the GWAS data were included in this study. The polygenic risk scores based on AF-associated SNPs were determined and then integrated with Phenome-wide association study (PheWAS)-derived risk factors including clinical and demographic variables. The robust AF predictive models were developed through advanced statistical and machine learning techniques and then were evaluated in terms of discrimination, calibration, and clinical utility.RESULTS: The results demonstrated that the top 30 significant SNPs associated with AF were located on chromosomes 10 and 16, which involved NEURL1, SH3PXD2A, INA, NT5C2, STN1, and ZFHX3 genes with INA, NT5C2, and STN1 being new discoveries in association with AF. The GWAS predictive power for AF had an area under the curve (AUC) of 0.626 (P < 0.001) and 0.851 (P < 0.001) before and after adjusting with age and gender, respectively. The results of PheWAS analysis showed that the top 10 diseases associated with discovered genes were all circulatory system diseases. The results of this study suggested that AF could be predicted by genetic information alone with moderate accuracy. The GWAS could be a robust and useful tool for detecting polygenic diseases by capturing the cumulative effects and genetic interactions of moderately associated but statistically significant SNPs.CONCLUSIONS: By integrating genetic and phenotypic data, the accuracy and clinical relevance of predictive models for AF were improved. The results of this study might improve AF risk classification, enable personalized interventions, and ultimately reduce the burden of AF-related morbidity and mortality.Graphic Abstract Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementThis work was supported by China Medical University and China Medical University Hospital in Taiwan (grant nos. CMU110-N-30 and DMR-112-126).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CMUH ethics committees (Approval number: CMUH111-REC1-176, CMUH107-REC3-058, and CMUH110-REC3-005).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableThe datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.